SBMFF OTC
Sino Biopharmaceutical Limited
1W: +0.0%
1M: -5.8%
3M: +17.2%
YTD: -20.3%
1Y: -36.2%
3Y: +111.9%
5Y: -9.8%
$0.69
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Cash Flow Trends
Operating Cash Flow
$6.6B
+9.1% ▲
5Y CAGR: +4.4%
Capital Expenditures
$960M
+43.6% ▲
5Y CAGR: -11.2%
Free Cash Flow
$5.7B
+29.6% ▲
5Y CAGR: +9.5%
Dividends Paid
$1.8B
-191.8% ▼
Buybacks
$1.3B
-215.9% ▼
Net Change in Cash
-$1.3B
-10.8% ▼
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | $5.0B | $18.6B | $5.8B | $5.9B | $3.5B |
| Depreciation & Amort. | $1.7B | $993M | $1.0B | $1.1B | $1.3B |
| Stock-Based Comp. | $0 | $0 | $30M | $18M | $54M |
| Change in Working Capital | $261M | -$339M | -$196M | -$431M | $27M |
| Other Non-Cash Items | -$1.6B | -$13.9B | -$395M | -$530M | $1.7B |
| Operating Cash Flow | $5.3B | $5.4B | $6.3B | $6.1B | $6.6B |
| — Investing Activities — | |||||
| Capital Expenditures | -$1.9B | -$1.9B | -$1.7B | -$1.1B | $0 |
| Acquisitions (Net) | -$4.2B | -$959M | -$59M | -$743M | $0 |
| Investment Purchases | -$7.2B | -$4.8B | -$4.5B | -$1.7B | $0 |
| Investment Sales | $5.1B | $903M | $1.1B | $2.6B | $0 |
| Other Investing | $250M | $4.3B | $1.1B | $142M | -$1.7B |
| Investing Cash Flow | -$7.8B | -$2.5B | -$4.1B | -$757M | -$1.7B |
| — Financing Activities — | |||||
| Net Debt Issuance | $5.4B | -$1.6B | $1.0B | -$1.8B | -$2.8B |
| Stock Repurchased | -$195M | -$333M | -$868M | -$396M | -$1.3B |
| Dividends Paid | -$1.2B | -$938M | -$1.3B | -$633M | -$1.8B |
| Other Financing | -$1.8B | -$316M | -$2.1B | -$3.8B | -$437M |
| Financing Cash Flow | $2.2B | -$3.2B | -$3.2B | -$6.5B | -$6.3B |
| Net Change in Cash | -$7M | -$1.0B | -$945M | -$1.1B | -$1.3B |
| Cash End of Period | $10.6B | $9.6B | $8.7B | $7.5B | $6.2B |
| Free Cash Flow | $3.5B | $3.5B | $4.6B | $4.4B | $5.7B |